The abstract is read at the publisher; the summary is JClub's.
Pretreatment ctDNA burden is prognostic in localized and metastatic Ewing sarcoma, with hazard ratios of 2.36 (P=.032) and 2.15 (P=.001), respectively.
- Why it matters: Risk stratification in Ewing sarcoma is a priority, but discrete, clinically actionable groups need prospective validation of circulating biomarkers tied to outcomes.
- What they did: In the LEOPARD biology study and embedded AEWS1221 metastatic trial, baseline blood was analyzed by ultralow-pass whole-genome sequencing and hybrid capture for ctDNA quantification, fusion detection, and STAG2/TP53 alterations. Associations were tested across 140 localized and 255 metastatic evaluable pretreatment samples, with serial ctDNA sequencing in a subset.
- The result: Elevated baseline ctDNA predicted inferior outcomes in both settings, and integrating ctDNA burden with clinical-molecular features defined low-, intermediate-, and high-risk groups, including a localized low-risk group with no events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.